Chiauranib Slows Platinum-Resistant Ovarian Cancer
The phase 3 CHIPRO trial has shown that the investigational drug chiauranib, when added to weekly paclitaxel, improves progression-free survival in patients with platinum-resistant ovarian cancer. The trial involved over 400 patients and demonstrated a significant extension in progression-free survival, although overall survival did not improve. Researchers noted the trial's relevance due to its inclusion of a substantial number of platinum-refractory patients.
- ▪The CHIPRO trial found that chiauranib extended progression-free survival to 4.6 months compared to 2.7 months with placebo.
- ▪The overall response rate was 32% in the chiauranib group versus 14.3% in the placebo group.
- ▪Treatment-emergent adverse events of grade 3 or worse affected 90% of patients receiving chiauranib.
Opening excerpt (first ~120 words) tap to expand
Adding the investigational multi-kinase inhibitor chiauranib to weekly paclitaxel improves progression-free survival among patients with platinum-resistant or platinum-refractory ovarian cancer, according to findings from the phase 3 CHIPRO trial.The trial, involving over 400 patients in China, found that chiauranib extended progression-free survival to 4.6 months vs 2.7 months with weekly paclitaxel plus placebo. That translated to a 57% reduction in the risk for progression or death.Notably, about 10% of patients in the trial had platinum-refractory disease, and roughly 70% had previously received anti-angiogenic therapy.“CHIPRO is the first randomized study with a substantial primary platinum-refractory population, making it highly relevant to real-world practice,” researcher Xiaohua…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
